Evaluation of efficacy and safety of first-line docetaxel/cisplatin/5-FU combined therapy for advanced esophageal cancer

We retrospectively evaluated the efficacy and safety of a first-line combination chemotherapy with Docetaxel, Cisplatin, and 5-fluorouracil (DCF therapy) in nine patients with advanced esophageal cancer. Dose administrated were 75 mg/m² of Docetaxel on day 1, 75 mg/m² of CDDP on day 1, and 750 mg/m²...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 38; no. 3; p. 393
Main Authors Minowa, Mayumi, Kinoshita, Yoshihiro, Hasebe, Shinobu, Ito, Tadaaki, Ogawa, Masako, Takebayashi, Katsushi, Ehara, Kazuhisa, Ueno, Masaki, Udagawa, Harushi, Hayashi, Masahiro
Format Journal Article
LanguageJapanese
Published Japan 01.03.2011
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - administration & dosage
Cisplatin - adverse effects
Cisplatin - therapeutic use
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Fluorouracil - therapeutic use
Humans
Male
Middle Aged
Neoplasm Staging
Taxoids - administration & dosage
Taxoids - adverse effects
Taxoids - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:We retrospectively evaluated the efficacy and safety of a first-line combination chemotherapy with Docetaxel, Cisplatin, and 5-fluorouracil (DCF therapy) in nine patients with advanced esophageal cancer. Dose administrated were 75 mg/m² of Docetaxel on day 1, 75 mg/m² of CDDP on day 1, and 750 mg/m² of 5-FU on day 1-5. Complete response (CR) in two patients (22. 2%), partial response (PR)in three patients ( 33. 3%), and no change (NC) in four patients (55. 6%) were shown for main lesions, while CR in one (11. 1%), PR in five (55. 6%), and NC in three (33. 3%) were shown for lymph node metastases. Response rates of the DCF therapy were 55. 6% for main lesions and 66. 7% for lymph node metastases. Five patients who achieved PR or CR underwent esophagectomy with lymph node dissection. Toxicity from DCF therapy was grade 3 or 4 emergent adverse events (77. 8% of neutropenia, 55. 6% of febrile neutropenia, and 55. 6% of anorexia). DCF therapy improved the response rate in esophageal cancer patients, but resulted in some increase in toxicity. Prospective study with prevention of toxicity should be planned in order to evaluate first-line DCF therapy for advanced esophageal cancer.
ISSN:0385-0684